We are committed to furthering psychedelic research globally and have developed licensing partnerships with leading researchers, institutions, and organizations around the world.
Our manufacturing facility has the capacity to supply every psilocybin clinical trial in the world.
We know that the advancement of psychedelic research is critical for getting patients access to the treatments they need. We are dedicated to delivering low- or no-cost study drugs for academic researchers and are also expanding our network of commercial licensing partnerships.
Clinical trials are the optimal way for patients to access our drugs before they obtain marketing authorization.
Please reach out to us for information on clinical trials in your jurisdiction.
Filament is undertaking a clinical development program in order to apply for marketing authorization in various jurisdictions. As such, the safety and efficacy of our products has not yet been established.
Through Health Canada’s Special Access Program (SAP), health care professionals may request access to non-marketed drugs to treat patients with serious or life-threatening conditions. Access to these drugs is only considered when conventional therapies have failed, are unsuitable, or are unavailable.
SAP authorization allows a manufacturer to sell a drug that has not been approved for sale in Canada. Drugs considered for release under SAP include pharmaceutical, biologic, and radiopharmaceutical products.
Learn more from Health Canada about how to request special access to an unapproved drug.
Oops! Something went wrong while submitting the form.